Before the Bell Scans: Dynavax Technologies, Warner Chilcott, Avanir Pharma, and Actavis PR Newswire LONDON, June 19, 2013 LONDON, June 19, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Drug manufacturers in the U.S., as well as globally, have been facing increasing competition from generic drug makers following the expiration of patents on several blockbuster drugs. In 2013 alone, patents on drugs with annual sales of nearly $30 billion are set to expire. This will lead to further generic competition. The "patent cliff" has created significant challenges for drug manufacturers. The key for drug companies will be to boost their product pipelines and collaborate with institutions and biotechnology companies that have developed, or are developing, potential blockbuster drugs. On Tuesday, June 18, 2013, shares in drug manufacturers and generic drug companies ended mostly higher, tracking gains in the broader market. The major movers in the sector included Dynavax Technologies Corporation (NASDAQ: DVAX), Warner Chilcott Plc (NASDAQ: WCRX), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), and Actavis Inc. (NYSE: ACT). All these companies are tracked by AAAResearchReports.com. Free technical research on DVAX, WCRX, AVNR, and ACT can be downloaded upon sign up at http://www.aaaresearchreports.com/register/ Shares in Dynavax Technologies Corporation tumbled on Tuesday, extending their losses from previous trading sessions. The company's shares hit a 52-week low of $0.99 before finishing the day 5.45% lower at $1.04. A total of 6.57 million shares were traded, which is well above the daily average volume of 3.30 million. The drug manufacturer's shares have declined by over 13.30% in the last three sessions, and so far this year, the stock has tumbled over 62.00%. Besides, the company's shares are currently trading 79.61% below their 52-week high. Sign up today to read free research report on DVAX at: http://www.AAAResearchReports.com/DVAX061913.pdf Warner Chilcott Plc's stock moved 0.33% higher yesterday, reversing some of its recent losses. The company's shares traded between $19.64 and $19.88 before closing the day at $19.75 on a total of 3.44 million shares traded, which is well below the daily average volume of 10.64 million. Shares of this drug maker have dropped by nearly 1.40% in the last three sessions. Since the start of 2013, the stock has gained over 68.00%, thus outperforming the S&P 500. The company's shares are currently trading well above their 50-day and 200-day moving averages. Register to download free technical analysis on WCRX at: http://www.AAAResearchReports.com/WCRX061913.pdf Shares in Avanir Pharmaceuticals Inc. rose sharply on Tuesday, extending their gains from the previous market sessions. The company's shares hit an intraday high of $4.62 before ending the day 2.10% higher at $4.61. It also saw a total of 3.02 million shares traded which is well above the daily average volume of 2.00 million. Shares of Avanir Pharma have jumped by over 8.20% in the last three sessions. So far this year, the stock has gained over 79.00%, hence outperforming the S&P 500. Moreover, the company's shares are currently trading 3.56% below their 52-week high. A free report on AVNR can be accessed by registering at: http://www.AAAResearchReports.com/AVNR061913.pdf Actavis Inc.'s stock saw a surge on Tuesday, closing at $125.67, up 0.58% from its previous closing price. The company's shares traded between $124.44 and $126.27 on total of 621,683 shares traded which is well below the daily average volume of 2.06 million. Actavis' shares are now down by over 0.60% in the last three trading sessions. Furthermore, the stock is currently trading above its 50-day and 200-day moving averages. Register with AAA Research Reports and download the research on ACT for free at: http://www.AAAResearchReports.com/ACT061913.pdf EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE AAA Research Reports Contact: Media Contact: AAAresearchreports.com, Phone #: +1-(646)-396-9126
Before the Bell Scans: Dynavax Technologies, Warner Chilcott, Avanir Pharma, and Actavis
Press spacebar to pause and continue. Press esc to stop.